erce-shutterstock-com-lifeblood-

Erce / Shutterstock.com

7 December 2016Big Pharma

LSPN 2016: IP is ‘lifeblood’ of life sciences industry

Intellectual property is the lifeblood of the life sciences industry and innovation is key, according to Nicola Dagg, head of Allen & Overy’s IP litigation practice in London.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Court denies Regeneron bid to halt copy of blockbuster eye drug

Interview: Klaus Grabinski, UPC Court of Appeal president

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird

Sandoz wins $137.2m payout for lost profits in generic launch

Sanofi signs global rights deal to develop rare cancer therapy

Unified Patent Court visualised: Cases, divisions, and classes in charts